Cancers,
Journal Year:
2023,
Volume and Issue:
15(5), P. 1417 - 1417
Published: Feb. 23, 2023
Lactic
acidosis,
a
hallmark
of
solid
tumour
microenvironment,
originates
from
lactate
hyperproduction
and
its
co-secretion
with
protons
by
cancer
cells
displaying
the
Warburg
effect.
Long
considered
side
effect
metabolism,
lactic
acidosis
is
now
known
to
play
major
role
in
physiology,
aggressiveness
treatment
efficiency.
Growing
evidence
shows
that
it
promotes
cell
resistance
glucose
deprivation,
common
feature
tumours.
Here
we
review
current
understanding
how
extracellular
acting
as
combination
enzymatic
inhibitors,
signal,
nutrient,
switch
metabolism
an
oxidative
metabolic
phenotype,
which
allows
withstand
makes
promising
anticancer
target.
We
also
discuss
about
acidosis’
could
be
integrated
whole-tumour
what
perspectives
opens
up
for
future
research.
Cancer Medicine,
Journal Year:
2023,
Volume and Issue:
12(12), P. 13784 - 13799
Published: May 3, 2023
Metabolic
disorders
are
a
hallmark
feature
of
cancer.
However,
the
evidence
for
causality
circulating
metabolites
to
promote
or
prevent
colorectal
cancer
(CRC)
is
still
lacking.
We
performed
two-sample
Mendelian
randomization
(MR)
analysis
assess
from
genetically
proxied
486
blood
CRC.Genome-wide
association
study
(GWAS)
data
exposures
were
extracted
7824
Europeans
GWAS
on
metabolite
levels.
CRC
catalog
database
GCST012879
used
preliminary
analysis.
The
random
inverse
variance
weighted
(IVW)
primary
while
MR-Egger
and
median
as
complementary
analyses.
Cochran
Q
test,
intercept
MR-PRESSO,
Radial
MR,
leave-one-out
sensitivity
For
significant
associations,
additional
independent
GCST012880
replication
meta-analysis.
final
identification
metabolites,
Steiger
linkage
disequilibrium
score
regression,
colocalization
further
evaluation.
Multivariable
MR
was
direct
effect
CRC.The
results
this
indicated
associations
between
six
pyruvate
(odds
ratio
[OR]:
0.49,
95%
confidence
interval
[CI]:
0.32-0.77,
p
=
0.002),
1,6-anhydroglucose
(OR:
1.33,
CI:
1.11-1.59,
nonadecanoate
(19:0)
0.40,
C
I:0.4-0.68,
0.0008),
1-linoleoylglycerophosphoethanolamine
0.47,
0.30-0.75,
0.001),
2-hydroxystearate
0.39,
0.23-0.67,
0.0007),
gamma-glutamylthreonine
2.14,
1.02-4.50,
0.040)
CRC.
MVMR
revealed
that
predicted
pyruvate,
can
directly
influence
independently
other
metabolites.The
current
work
provides
support
new
perspective
exploration
biological
mechanisms
by
combining
genomics
metabolomics.
These
findings
contribute
screening,
prevention
treatment
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2023,
Volume and Issue:
42(1)
Published: Sept. 29, 2023
Abstract
Background
Chimeric
antigen
receptor
(CAR)-T
immunotherapy
fails
to
treat
solid
tumors
due
in
part
immunosuppressive
microenvironment.
Excess
lactate
produced
by
tumor
glycolysis
increases
CAR-T
immunosuppression.
The
mechanism
of
inducing
the
formation
microenvironment
remains
be
further
explored.
Methods
Immunocyte
subpopulations
and
molecular
characteristics
were
analyzed
orthotopic
xenografts
nude
mice
using
flow
cytometry
assay
immunohistochemical
staining
after
oxamate,
a
dehydrogenase
A
(LDHA)
inhibitor,
control
T
or
cells
injection
alone
combination.
RT-qPCR,
western
blot,
cytometry,
immunofluorescence,
luciferase
reporter
assay,
chromatin
immunoprecipitation
ELISA
performed
measure
effect
on
regulation
CD39,
CD73
CCR8
cultured
glioma
stem
cells,
CD4
+
macrophages.
Results
Oxamate
promoted
immune
activation
tumor-infiltrating
through
altering
phenotypes
molecules
increasing
regulatory
(Treg)
infiltration
glioblastoma
mouse
model.
Lactate
accumulation
within
upregulated
expressions
both
lactate-treated
cells-co-cultured
macrophages,
intracellular
directly
elevated
activities
these
gene
promotors
histone
H3K18
lactylation.
Conclusions
Utilizing
generation
inhibitor
not
only
reprogramed
glucose
metabolism
cancer
but
also
alleviated
immunosuppression
reduced
CAR-Treg
which
may
potential
strategy
enhance
function
therapy.
Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(19)
Published: Jan. 18, 2024
Abstract
Hydrogen
sulfide
(H
2
S)
is
being
progressively
integrated
as
an
emerging
inhibitor
of
the
electron
transport
chain
in
energy
interference‐based
tumor
therapy.
However,
metabolic
reprogramming
cancer
cells
causes
both
oxidative
phosphorylation
(OXPHOS)
and
glycolysis
to
occur
simultaneously,
which
contributes
ineffective
therapeutic
effect
blocking
a
single
pathway.
To
achieve
complete
suppression
production,
inorganic
H
S
donor
ZnS@ZIF‐8@CaP
nanoparticle
(ZSZC
NP)
carrying
Ca
Zn
constructed
for
achieving
simultaneous
interference
OXPHOS
glycolysis.
The
core–shell
ZSZC
nanoparticles
can
break
down
microenvironment.
This
leads
sustained
release
calcium
overload
disrupt
normal
functioning
mitochondria
by
inhibiting
expression
cytochrome
c
causing
damage
mitochondrial
membrane
potential.
Meanwhile,
presence
2+
hinders
typical
process
impeding
lactate
dehydrogenase
glyceraldehyde‐3‐phosphate
dehydrogenase.
synchronous
hampers
supply
cells.
Additionally,
expedite
necrosis
vivo
inducing
cellular
acidification
calcification.
Therefore,
this
energy‐blocking
strategy
will
completely
deplete
reserves
provide
new
insights
exploring
bioenergetic
inhibition
treatment
approach.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Aug. 16, 2024
Cuproptosis
is
a
newly
identified
form
of
cell
death
induced
by
excessive
copper
(Cu)
accumulation
within
cells.
Mechanistically,
cuproptosis
results
from
Cu-induced
aggregation
dihydrolipoamide
S-acetyltransferase,
correlated
with
the
mitochondrial
tricarboxylic
acid
cycle
and
loss
iron–sulfur
cluster
proteins,
ultimately
resulting
in
proteotoxic
stress
triggering
death.
Recently,
has
garnered
significant
interest
tumor
research
due
to
its
potential
as
crucial
therapeutic
strategy
against
cancer.
In
this
review,
we
summarized
cellular
molecular
mechanisms
relationship
other
types
Additionally,
reviewed
current
drugs
or
strategies
available
induce
cells,
including
Cu
ionophores,
small
compounds,
nanomedicine.
Furthermore,
targeted
metabolism
specific
regulatory
genes
cancer
therapy
enhance
sensitivity
cuproptosis.
Finally,
discussed
feasibility
targeting
overcome
chemotherapy
immunotherapy
resistance
suggested
future
directions.
This
study
that
could
open
new
avenues
for
developing
therapy.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: Feb. 11, 2025
Abstract
Accumulated
evidence
has
implicated
the
diverse
and
substantial
influence
of
lactate
on
cellular
differentiation
fate
regulation
in
physiological
pathological
settings,
particularly
intricate
conditions
such
as
cancer.
Specifically,
been
demonstrated
to
be
pivotal
molding
tumor
microenvironment
(TME)
through
its
effects
different
cell
populations.
Within
cells,
impacts
signaling
pathways,
augments
shuttle
process,
boosts
resistance
oxidative
stress,
contributes
lactylation.
In
various
populations,
interplay
between
immune
cells
governs
processes
differentiation,
response,
surveillance,
treatment
effectiveness.
Furthermore,
communication
stromal/endothelial
supports
basal
membrane
(BM)
remodeling,
epithelial-mesenchymal
transitions
(EMT),
metabolic
reprogramming,
angiogenesis,
drug
resistance.
Focusing
production
transport,
specifically
dehydrogenase
(LDH)
monocarboxylate
transporters
(MCT),
shown
promise
Inhibitors
targeting
LDH
MCT
act
both
suppressors
enhancers
immunotherapy,
leading
a
synergistic
therapeutic
effect
when
combined
with
immunotherapy.
The
review
underscores
importance
progression
provides
valuable
perspectives
potential
approaches
that
target
vulnerability
metabolism,
highlighting
Heel
Achilles
for
cancer
treatment.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 14, 2025
Glioblastoma(GBM)
is
a
highly
malignant
primary
central
nervous
system
tumor
that
poses
significant
threat
to
patient
survival
due
its
treatment
resistance
and
rapid
recurrence.Current
options,
including
maximal
safe
surgical
resection,
radiotherapy,
temozolomide
(TMZ)
chemotherapy,
have
limited
efficacy.In
recent
years,
the
role
of
glycolytic
metabolic
reprogramming
in
GBM
has
garnered
increasing
attention.
This
review
delves
into
pivotal
GBM,
with
particular
focus
on
multifaceted
roles
lactate,
key
product,
within
microenvironment
(TME).
Lactate
been
implicated
promoting
cell
proliferation,
invasion,
immune
evasion.
Additionally,
this
systematically
analyzes
potential
therapeutic
strategies
targeting
molecules
pathway,
such
as
Glucose
Transporters
(GLUTs),
Monocarboxylate
Transporters(MCTs),
Hexokinase
2
(HK2),
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase
3
(PFKFB3),
Pyruvate
Kinase
Isozyme
Type
M2
(PKM2),
Dehydrogenase
A
(LDHA).
These
studies
provide
novel
perspective
for
treatment.
Despite
progress
made
existing
research,
challenges
remain,
drug
penetration
across
blood-brain
barrier,
side
effects,
resistance.
Future
research
will
aim
address
these
by
improving
delivery,
minimizing
exploring
combination
therapies
immunotherapy
develop
more
precise
effective
personalized
GBM.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Aug. 14, 2023
As
critical
executors
regulating
many
cellular
operations,
proteins
determine
whether
living
activities
can
be
performed
in
an
orderly
and
efficient
manner.
Precursor
are
inert
must
modified
posttranslationally
to
enable
a
wide
range
of
protein
types
functions.
Protein
posttranslational
modifications
(PTMs)
well
recognized
as
being
directly
associated
with
carcinogenesis
immune
modulation
have
emerged
important
targets
for
cancer
detection
treatment.
Lactylation
(Kla),
novel
PTM
metabolism
found
cells,
interacts
both
histone
nonhistone
proteins.
Unlike
other
epigenetic
changes,
Kla
has
been
linked
poor
tumor
prognosis
all
current
studies.
Histone
affect
gene
expression
tumors
immunological
thereby
promoting
malignancy
immunosuppression.
Nonhistone
also
regulate
progression
treatment
resistance
through
Kla.
In
this
review,
we
aimed
summarize
the
role
onset
cancers,
metabolic
reprogramming,
immunosuppression,
intestinal
flora
regulation
identify
new
molecular
therapy
provide
direction
combined
targeted
immunotherapy.